Arovella Therapeutics Ltd

E4NA

Company Profile

  • Business description

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

  • Contact

    84 Hotham Street
    Corporate One
    PrestonVIC3072
    AUS

    T: +61 398636472

    https://www.arovella.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    44

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,815.305.00-0.06%
CAC 407,829.2972.96-0.92%
DAX 4024,255.31201.50-0.82%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,941.1234.54-0.38%
HKSE24,239.4799.900.41%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,459.62110.06-0.28%
NZX 50 Index12,678.697.99-0.06%
S&P 5006,259.7520.71-0.33%
S&P/ASX 2008,570.409.70-0.11%
SSE Composite Index3,528.6718.490.53%

Market Movers